Suggested remit: To appraise the clinical and cost effectiveness of garadacimab within its marketing authorisation for preventing acute attacks of hereditary angioedema.
 
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6394

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
28 June 2024 - 26 July 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6394
28 June 2024 In progress. Scoping commencing
14 November 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
09 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual